Cargando…

N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment

BACKGROUND: Increasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators and the immune microenvironment, providing a potential therapeutic target for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yanlong, Wang, Yizhu, Zhang, Wenning, Niu, Kaiyi, Mao, Xinyu, Feng, Kun, Zhang, Yewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352105/
https://www.ncbi.nlm.nih.gov/pubmed/37469973
http://dx.doi.org/10.3389/fendo.2023.1153802
_version_ 1785074447160442880
author Shi, Yanlong
Wang, Yizhu
Zhang, Wenning
Niu, Kaiyi
Mao, Xinyu
Feng, Kun
Zhang, Yewei
author_facet Shi, Yanlong
Wang, Yizhu
Zhang, Wenning
Niu, Kaiyi
Mao, Xinyu
Feng, Kun
Zhang, Yewei
author_sort Shi, Yanlong
collection PubMed
description BACKGROUND: Increasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators and the immune microenvironment, providing a potential therapeutic target for patients with hepatocellular carcinoma (HCC). METHODS: Totals of 371 HCC and 50 normal patients were included in this study. GSE121248 and GSE40367 datasets were used to validate the expression of HNRNPC. The R package “ConsensusClusterPlus” was performed to screen consensus clustering types based on the expression of m6A regulators in HCC. The R package “pheatmap”, “immunedeconv”, “survival”, “survminer” and “RMS” were applied to investigate the expression, immunity, overall survival, and clinical application in different clusters and expression groups. Comprehensive analysis of HNRNPC in pan-cancer was conducted by TIMER2 database. Besides, HNRNPC mRNA and protein expression were verified by qRT-PCR and immunohistochemistry analysis. RESULTS: Most of m6A regulators were over-expressed excerpt for ZC3H13 in HCC. Three independent clusters were screened based on m6A regulators expression, and the cluster 2 had a favorable prognosis in HCC. Then, the cluster 2 was positively expression in macrophage, hematopoietic stem cell, endothelial cell, and stroma score, while negatively in T cell CD4(+) memory and mast cell. We identified HNRNPC was an independent prognostic factor in HCC, and nomogram performed superior application value for clinical decision making. Moreover, PD-L1 was significantly up-regulated in HCC tissues, cluster 1, and cluster 3, and we found PD-L1 expression was positively correlated with HNRNPC. Patients with HCC in high-expression groups was associated with tumor-promoting cells. Besides, HNRNPC was correlated with prognosis, TMB, and immune checkpoints in cancers. Particularly, the experiments confirmed that HNRNPC was positively expression in HCC cells and tissues. CONCLUSION: The m6A regulators play irreplaceable roles in prognosis and immune infiltration in HCC, and the relationship of HNRNPC and PD-L1 possesses a promising direction for therapeutic targets of immunotherapy response. Exploration of m6A regulators pattern could be build the prognostic stratification of individual patients and move toward to personalized treatment.
format Online
Article
Text
id pubmed-10352105
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103521052023-07-19 N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment Shi, Yanlong Wang, Yizhu Zhang, Wenning Niu, Kaiyi Mao, Xinyu Feng, Kun Zhang, Yewei Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Increasing evidence elucidated N6-methyladenosine (m6A) dysregulation participated in regulating RNA maturation, stability, and translation. This study aimed to demystify the crosstalk between m6A regulators and the immune microenvironment, providing a potential therapeutic target for patients with hepatocellular carcinoma (HCC). METHODS: Totals of 371 HCC and 50 normal patients were included in this study. GSE121248 and GSE40367 datasets were used to validate the expression of HNRNPC. The R package “ConsensusClusterPlus” was performed to screen consensus clustering types based on the expression of m6A regulators in HCC. The R package “pheatmap”, “immunedeconv”, “survival”, “survminer” and “RMS” were applied to investigate the expression, immunity, overall survival, and clinical application in different clusters and expression groups. Comprehensive analysis of HNRNPC in pan-cancer was conducted by TIMER2 database. Besides, HNRNPC mRNA and protein expression were verified by qRT-PCR and immunohistochemistry analysis. RESULTS: Most of m6A regulators were over-expressed excerpt for ZC3H13 in HCC. Three independent clusters were screened based on m6A regulators expression, and the cluster 2 had a favorable prognosis in HCC. Then, the cluster 2 was positively expression in macrophage, hematopoietic stem cell, endothelial cell, and stroma score, while negatively in T cell CD4(+) memory and mast cell. We identified HNRNPC was an independent prognostic factor in HCC, and nomogram performed superior application value for clinical decision making. Moreover, PD-L1 was significantly up-regulated in HCC tissues, cluster 1, and cluster 3, and we found PD-L1 expression was positively correlated with HNRNPC. Patients with HCC in high-expression groups was associated with tumor-promoting cells. Besides, HNRNPC was correlated with prognosis, TMB, and immune checkpoints in cancers. Particularly, the experiments confirmed that HNRNPC was positively expression in HCC cells and tissues. CONCLUSION: The m6A regulators play irreplaceable roles in prognosis and immune infiltration in HCC, and the relationship of HNRNPC and PD-L1 possesses a promising direction for therapeutic targets of immunotherapy response. Exploration of m6A regulators pattern could be build the prognostic stratification of individual patients and move toward to personalized treatment. Frontiers Media S.A. 2023-07-03 /pmc/articles/PMC10352105/ /pubmed/37469973 http://dx.doi.org/10.3389/fendo.2023.1153802 Text en Copyright © 2023 Shi, Wang, Zhang, Niu, Mao, Feng and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Shi, Yanlong
Wang, Yizhu
Zhang, Wenning
Niu, Kaiyi
Mao, Xinyu
Feng, Kun
Zhang, Yewei
N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
title N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
title_full N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
title_fullStr N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
title_full_unstemmed N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
title_short N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
title_sort n6-methyladenosine with immune infiltration and pd-l1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352105/
https://www.ncbi.nlm.nih.gov/pubmed/37469973
http://dx.doi.org/10.3389/fendo.2023.1153802
work_keys_str_mv AT shiyanlong n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment
AT wangyizhu n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment
AT zhangwenning n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment
AT niukaiyi n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment
AT maoxinyu n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment
AT fengkun n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment
AT zhangyewei n6methyladenosinewithimmuneinfiltrationandpdl1inhepatocellularcarcinomanovelperspectivetopersonalizeddiagnosisandtreatment